In summary, our findings draw attention to the widespread use of AR-targeted therapy and the emergence of adaptive resistance mechanisms related to ARHGEF2 that promote neuroendocrine differentiation in anti-androgen-induced PCa. The gene discussed is ARHGEF2; the disease is posterior cortical atrophy.